German vaccine maker BioNTech SE (NASDAQ:BNTX) revealed on May 20 that it intends to boost its presence in the UK with an investment of up to £1 billion ($1.33 billion) over the next decade, focusing ...

As well as the economic and employment benefits, BioNTech’s UK investment is expected to deliver tangible improvements in healthcare. The company’s work in personalised cancer immunotherapies, already ...

"BioNTech to invest up to $1.34bn in UK R&D" was originally created and published by Pharmaceutical Technology, a GlobalData ...

The new framework unveiled May 20 says new COVID-19 shots should go only to those ages 65 and up or with underlying medical conditions.

The FDA will narrow its approval for updated coronavirus vaccines, marking a significant shift in the agency’s approach to ...

Shares of Vaccine stocks are moving higher on Tuesday after documents from the U.S. Food and Drug Administration revealed ...

In an editorial article published in the New England Journal of Medicine, Dr. Vinay Prasad, the newly appointed head of the ...

BioNTech said it plans to invest up to 1 billion pounds ($1.34 billion) over the next 10 years to expand its research and development activities for innovative medicines in the U.K.

Roughly five months after AstraZeneca scrapped a major investment plan in its home country, the United Kingdom has found a ...

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely ...

Biopharmaceutical company BioNTech has announced funding of up to £1 billion into the UK over the next 10 years. The planned investment would be one of the biggest in the history of UK life sciences, ...